Autonomix Completes Licensing Transaction for FDA-Cleared Ablation Technology
24 Luglio 2024 - 2:00PM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced it has
completed its previously announced transaction with RF Innovations,
Inc., a privately held medical technology company, to license the
intellectual property to its Apex 6 Radiofrequency Generator. The
transaction, for 250,000 shares of common stock, grants Autonomix a
perpetual non-exclusive worldwide and royalty-free license of the
Apex 6 Generator intellectual property, as well as enhances the
Autonomix supply chain with RF Innovations’ experienced
manufacturing partner.
The Apex 6 Generator is an FDA-cleared ablation
technology designed to lesion neural tissue for pain management in
the peripheral nervous system and will be a component of the
sensing and ablation system submitted to gain FDA clearance for
Autonomix’s technology. Autonomix plans to utilize the technology
in its strategic therapeutic areas to drive value across its
pipeline.
“The Apex 6 Generator’s compatibility with the
specifics for our radiofrequency generator ablation system de-risks
incremental product development and further accelerates our journey
towards FDA clearance. We are pleased to successfully execute this
transaction and advance the development and commercialization of
our innovative technology platform, which we believe has the
potential to fill an important unmet need for patients. With this
transaction now complete, we are focused on working with RF
Innovations’ manufacturing partner and integrating them into our
supply chain as quickly and efficiently as possible,” commented
Brad Hauser, President and Chief Executive Officer of
Autonomix.
To facilitate equipment development, activities
will begin immediately with RF Innovations’ manufacturing partner
who will be incorporated into Autonomix’s manufacturing supply
chain.
Autonomix is initially developing its technology
to address pancreatic cancer-related pain, with plans for follow-on
indications pending the results of the initial data. Current
approaches, primarily relying on opioids or invasive ethanol
injections, can provide only limited relief and may lead to risky
side effects. For more information about the Company’s technology,
please visit autonomix.com.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing technology for the
treatment of pain, with initial trials focused on pancreatic
cancer, a condition that causes debilitating pain and is without a
reliable solution. Our technology constitutes a platform to address
dozens of indications, including cardiology, hypertension and
chronic pain management, across a wide disease spectrum. Our
technology is investigational and has not yet been cleared for
marketing in the United States.
For more information, visit autonomix.com and
connect with the Company on X, LinkedIn, Instagram and
Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Forward looking statements in this press release
include, without limitation, the ability of Autonomix to adapt the
licensed technology for its specific use case. Such forward-looking
statements can be identified by the use of words such as “should,”
“might,” “may,” “intends,” “anticipates,” “believes,” “estimates,”
“projects,” “forecasts,” “expects,” “plans,” “can,” and
“proposes.”
Although Autonomix believes that the
expectations reflected in these forward-looking statements are
based on reasonable assumptions, there are a number of risks and
uncertainties that could cause actual results to differ materially
from such forward-looking statements. You are urged to carefully
review and consider any cautionary statements and other
disclosures, including the statements made under the heading “Risk
Factors” and elsewhere in the Annual Report on Form 10-K filed with
the U.S. Securities and Exchange Commission (“SEC”) on May 31,
2024. Forward-looking statements speak only as of the date of the
document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media Contact
JTC Team, LLCJenene Thomas
833-475-8247autonomix@jtcir.com
Grafico Azioni Autonomix Medical (NASDAQ:AMIX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Autonomix Medical (NASDAQ:AMIX)
Storico
Da Dic 2023 a Dic 2024